Skip to main content
DAEWOONG CO.,LTD logo

DAEWOONG CO.,LTD — Investor Relations & Filings

Ticker · 003090 ISIN · KR7003090008 KO Manufacturing
Open in API
Filings indexed 311 across all filing types
Latest filing 2021-02-22 Director's Dealing
Country KR South Korea
Listing KO 003090

About DAEWOONG CO.,LTD

https://www.daewoong.co.kr

Daewoong Co., Ltd. is a holding company operating primarily in the biotechnology and healthcare sectors. Its core business, conducted through subsidiaries like Daewoong Pharmaceutical, involves the research, development, manufacturing, and commercialization of a broad range of pharmaceutical products. The company's portfolio includes prescription drugs, over-the-counter (OTC) medications, quasi-drugs, and active pharmaceutical ingredients (APIs). Daewoong focuses on developing innovative drugs, with established expertise in gastrointestinal and endocrine therapeutic areas. A key product in its global portfolio is Nabota, an FDA-approved botulinum toxin. The company emphasizes continuous R&D and engages in open collaboration to develop new healthcare solutions.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a standard Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This document is a mandatory disclosure filed with the Financial Supervisory Service (FSS) and the Korea Exchange (KRX) when a company executive or major shareholder changes their shareholding position. This corresponds to the 'Director's Dealing' category, which covers insider transactions and changes in ownership by company insiders.
2021-02-22 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders and Others' (최대주주등소유주식변동신고서) filed by Daewoong. It details specific changes in share ownership for company executives and related parties. This type of filing is a standard regulatory disclosure regarding insider shareholding changes, which falls under the 'Director's Dealing' category as it reports personal share transactions by company directors and executives.
2021-02-22 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경(자회사의 주요경영사항)
Earnings Release Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KRX) regarding a significant change in financial structure (30% or more change in revenue or profit). It provides preliminary financial data for the fiscal year, including revenue, operating profit, and net income, and explicitly notes that these figures are subject to change following an external audit. This is a standard 'Earnings Release' (ER) filing in the Korean market context, as it provides the initial announcement of financial results before the final audited annual report is published. FY 2020
2021-02-15 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경(자회사의 주요경영사항)
Earnings Release Classification · 100% confidence The document is a regulatory filing from Daewoong regarding a significant change in financial structure (30% or more change in revenue/profit) for its subsidiary, Daewoong Development. This is a standard Korean regulatory disclosure (DART system) for material financial changes. Since it is a specific regulatory announcement of financial results rather than a full report or a simple publication notice, it falls under the 'Regulatory Filings' category. FY 2020
2021-02-15 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Daewoong) announcing a significant change (over 30%) in revenue or profit structure. This is a standard regulatory disclosure requirement in the Korean market (DART system) for listed companies to provide preliminary financial results before the final audited report. It fits the 'Earnings Release' (ER) category as it provides key financial highlights and performance metrics for the fiscal year. FY 2020
2021-02-15 Korean
투자판단관련주요경영사항(자회사의 주요경영사항)(코로나치료제 DWJ1248의 COVID-19 예방 목적 임상3상 시험계획 승인)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Daewoong regarding the approval of a Phase 3 clinical trial for a COVID-19 treatment (DWJ1248). It is a specific disclosure of a material business event (major management matter) required by regulatory authorities. Since it does not fit into specific categories like financial reports, dividends, or M&A, it falls under the general regulatory announcement category.
2021-01-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.